Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you so much elm street for taking the initiative to visit Alliance Creative Group Inc, and talking with the executives and sharing your information and photos with us.
Me? I believe redemption is always possible. People can change and learn from their mistakes. The CEO's past, though, is an issue that people need to decide for themselves based on as much evidence and they can find if they are concerned about it. I know very little about the situation right now, but I think he may be fine.
I agree the CEO's past should be looked into, but you don't allow for people to change? Ever? No redemption? Extremely harsh, and short sighted in my opinion. Best of luck to you.
Makes sense for eventual uplisting. Thanks for the insight fj and Santo.
Why are you guessing this number for retired shares?
Dwyane Wade's foundation looks like a good cause for ACGX to be supporting. Glad to see that. I am holding 350,000 shares. Good luck!
Santo, I would very much appreciate hearing about what you see at Wialan. Thanks!
Corner, your statement was enough for me to take the time to look at the 10Q in Aug 2013. I didn't like what I saw. People might play this as a momo play (not for me!), but the financials, IMO, didn't look good.
On Friday, I emailed IR and asked when financials were due out. If I hear anything I will pass it along.
Thanks gypsyman! That is the kind of information I was hoping to hear. If he does take the helm of Wialan or BOD, then I will dig further. Thanks again.
Thanks Clay for ACYD video!
So far I like what I see about SITS, so for now I am holding. Good luck!
Curious who has been involved in old ACYD and what insights you might have about the rumor of Mitch Freifeld running the company. Obviously, somebody did something right to get this merger with Wialan.
I don't think his/her $5/share is based on numbers, but on wishful, hopeful speculation. A lot of unknowns for Wialan at this point, but it all looks good. Quite frankly, even 15 cent/share by August would be excellent for many, maybe most here. But right now we just don't have much in the way of real numbers to speculate realistically, so many go wild. BTW, If it is $5/share by August, even with my relatively small holdings, I couldn't afford to sell much at that point. Good luck!
Good info LuketheDuke and Benji-- and excellent photos wanamil, demonstrating Wialan's technology!
Good answer Benji to DCdaves question about comparing Wialan vs WIMAX. I suspect you have done more dd than most of us here. Thanks.
I did look at the ibox and I am not sure that the financing will be healthy overall. I could be wrong and be happy to be proven so. I will check in periodically just to see, but for now I am staying clear.
TOB, thanks for your posts. I had AAPH on my radar, but because of the toxic financing, I think I will just look elsewhere to put my investment dollars. You have saved me time combing through Qs and Ks to see what is in there.
I don't mind trading, but I also look at the fundamentals enough to make sure if the stock doesn't short term perform the way I had hoped I can decide whether to cut loses or hang on for the longer term. GLTY!
Are there any knowledgeable biotech investors (not traders) that have evaluated this stock? If so, what do you think of this company long range?
NVLX didn't conduct the P2s, but If you are interested in the results you could start here:
http://sgaustria.com/news/publications
Somewhere in there are peer reviewed results for P2 studies, I think around the year 2000. I no longer have this information on my current computer, but it should be in there somewhere. Have fun!
I wondered about the FDA accepting foreign P1 and P2 myself. I found an FDA document that addressed that issue:
Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND
Frequently Asked Questions
I admit that I have not carefully read the document, but skimmed it. While it doesn't look like US studies are automatically waived, it appear that P1 and P2 from foreign studies can be valid if certain criteria are met.
It is also my understanding that P2 are typically small, so I don't think size of the P2 is a problem; and I have no idea about how recent the study need have taken place.
I agree we may be some time away, if ever, from monetizing Cell-in-a-Box. This is very typical of biotech stocks. I think investors will take their cues about how the studies progress and how money is raised during the interim.
Good luck
Of course you should do your own research, but I wouldn't be surprised if the FDA had no record of P1 or P2 for NVLX. I believe the studies that were done were in Europe and were done by Austrianova Singapore (ASPL), or a previous company now owned by ASPL. The studies aren't new, but you can read about them at ASPL's website. I believe at least one of them was a peer reviewed article. Good luck.
Thanks for the specific reference to the Aug 2012 10-k.
In that I found the following statement:
"The Company has been working diligently to become a biotechnology and life technology company over the past year. As a result, the Company made major efforts to work with the principals and acquire Austrianova Singapore Private Limited ( “ Austrianova Singapore ” or ASPL), previously assets of SG Austria Private Limited or “ SG Austria, ” ) to advance research and to develop and market new biotechnologies and medical therapies. The acquisition was completed in June 2012 and Austrianova Singapore and Bio Blue Bird ( “ BBB ” ) became wholly-owned subsidiaries of Nuvilex, Inc. The Company business is that of an emerging biotechnology and life technology company which also contains Consumer Healthcare and Environmental Solutions Divisions."
I'm confused!! I don't know if this Bio Blue Bird (I assume not Bluebird Bio) is what I was expecting. I don't recall seeing this BBB referenced in the 10-Qs I've read. Maybe I missed it. I do recall seeing clearly statements about the acquisition of Austrianova Singapore. Nor do I find, after a quick look on SG Austria's site any info about Bio Blue Bird. I hope the company releases additional information soon about this acquisition.
I hope this is good news, but I don't know.
Re You state that the CEO was indicted for a pump and dump scheme, but was he CONVICTED?
The paid pumpers that were on your board are some of the same ones that were on another company board that I am invested in. I don't know if you can gauge their success on short term day to day prices. I think the idea is to annoy established investors (jk--sort of) and to bring awareness to a broader investor audience about the company. But it does look like they have moved on to other company boards.
Your comments are about the be swallowed up by the daily paid compensators. Thanks for the reply. I will continue to dig and see what I can find out, hopefully over the next few weeks. I would appreciate any real information you and other posters might have on the history of AG Austria and cell-in-box. I do think they have more recent publications than 1999. The fact that the study was published in Lancet, a very respected journal, makes me still a little hopeful. But if there hasn't been anything new since 1999, that would cause for concern.
I hope you are wrong and about the NVLX being a pump and dump, and cell-in-a-box being a scam. I am sure it takes a lot money to get something like this to market.
DB I hope that you are wrong about NVLX and its subsidiary SG Austria, but you do bring up some interesting points.
What do you think SG Austria, and its predecessor company, have been doing for the last 13 years? They were not a public company until NVLX came into the picture about a year ago. They must have been getting money from somewhere and doing some kinds of research. I also wonder why some bigger company has not come along and funded this technology. I don't know if SG Austria has a viable answer, but I do know that I had heard hopeful speculations about cell encapsulation 20 years ago from molecular biologists.
Good luck to you.
Thank you! I am long on NVLX as a very speculative stock. However, I am in no way suggesting that anyone else jump on board to buy the stock. I think the recent price movement is just a temporary momentum play,and until they have something recent and substantial to report it may very well drift down to where it was earlier in the year.
I don't know if their version of cell encapsulation will ultimately be the best, or most effective, or the medical winner. They have, however, published results in the past,eg:
Cancer Therapy Vol 1, 121-131, 2003.
Safety, feasibility and clinical benefit of localized
chemotherapy using microencapsulated cells for
inoperable pancreatic carcinoma in a phase I/II trial
There may be more recent peer reviewed studies, but this is the one I quickly found that pertains, I believe, to the P1/2 results.
GLTU
NVLX's subsidiary SG Austria have published the results of P1/2 already. Go to SG Austria's web page and read the results. There is nothing new to report, that I know of, at this time.
To the best of my knowledge NVLX has never claimed to be currently performing P3 studies. From what I understand the subsidiary company, SG Austria, is ramping up for P3 studies, but not currently conducting studies.
TheWatcher51: Re cell encapsulation, I don't know about patents, I think they may be European. As far as effectiveness I suggest you check out:
http://sgaustria.com/news/publications
As far as some of the other products held previously by NVLX, I don't think the company is focusing on their older products or direction. So those products may have been shelved, or looking for a buyer. I am not sure.
I wish the paid pumpers would end. I don't think, at this point it is helpful.
I don't know for sure if they are making a presentation or have an abstract, but I would guess that if they are it would be one of their scientist, and not be the company.
Thanks Fox! I was just trying to politely set the record straight.
I'm pretty sure that phase 2 trials included a small human population. So I don't think you comment is correct for Cell-in-a-Box technology.
Stayfocused, you are much quicker than I am. In the time it took me to compose my little paragraph you posted two detailed posting regarding NVLX phase 3 trials. :)
It is my understanding that the phase 3 trials are for the Cell-in-a-Box technology, not cannabinoids. I thought they would later incorporate the cannabinoids as one of the drugs incorporated with the Cell-in-a-Box. I think the Cell-in-a-Box has to meet with FDA approval separately from anything else they will use in conjunction with it: cannabinoids, insulin, ifosfamide , etc. Since, ifosfamide and insulin, I believe, have already been used I would think that one of those agents will continue into the phase 3 trials.
hallboy: What are you seeing that I am not? I am sorry to say that I don't feel like we are in the loop. I wish that they would release prs that are more substantial.
I realize the many momentum investors are excited by today’s announcement, but I have to wonder where the financing for this new division is coming from. So far as I know, NVLX has not even completed its financing of its subsidiary ASPL. As an existing stockholder, already in the hole with this investment, I hope they can pull it off, but I wonder if this is a good plan.
"Dr. Robert F. Ryan, emphasized, "The work to be carried out by Medical Marijuana Sciences, Inc. will not delay or dilute in any way Nuvilex's collaborative efforts with Austrianova Singapore to carry out planned late-stage clinical investigations using our unique, proprietary, living-cell encapsulation technology for pancreatic cancer and the development of treatments for a wide variety of diseases including other cancers, diabetes, diseases whose treatments may be based on stem cells, viral diseases, and others."
hbhmb: Is your comment intended for NVLX? If so can you elaborate or back up your comments with links and details? If not, maybe you want to have your comment deleted or moved to another board.
Sorry Fox I didn't see that you already posted basically the same info before I did. I think you got it right that ASPL needs cash for operations.